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Abstract
Background: In carbon ion radiotherapy (CIR) for esophageal cancer, organ and target motion is a major challenge
for treatment planning due to potential range deviations. This study intends to analyze the impact of intrafractional
variations on dosimetric parameters and to identify favourable settings for robust treatment plans.
Methods: We contoured esophageal boost volumes in different organ localizations for four patients and calculated
CIR-plans with 13 different beam geometries on a free-breathing CT. Forward calculation of these plans was
performed on 4D-CT datasets representing seven different phases of the breathing cycle. Plan quality was assessed
for each patient and beam configuration.
Results: Target volume coverage was adequate for all settings in the baseline CIR-plans (V95 > 98% for two-beam
geometries, > 94% for one-beam geometries), but reduced on 4D-CT plans (V95 range 50–95%). Sparing of the
organs at risk (OAR) was adequate, but range deviations during the breathing cycle partly caused critical, maximum
doses to spinal cord up to 3.5x higher than expected. There was at least one beam configuration for each patient
with appropriate plan quality.
Conclusions: Despite intrafractional motion, CIR for esophageal cancer is possible with robust treatment plans
when an individually optimized beam setup is selected depending on tumor size and localization.
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Background
Radiotherapy is a central component of neoadjuvant
or definitive concepts in multimodality treatment of
esophageal cancer [1, 2]. Despite several different
approaches to improve outcome over the past years by
treatment intensification through radiation dose escal-
ation or the addition of novel systemic agents [3, 4], a
major improvement has not been accomplished yet
resulting in a constantly high mortality rate for
esophageal cancer patients.
For standard photon-based irradiation, intensity-
modulated radiotherapy (IMRT) is recommended to
provide a reasonable dose conformity to the target vol-
ume [5] and has facilitated integrated boost concepts in
definitive treatment regimens [6]. Charged particle
radiotherapy with carbon ions has been introduced as a
new approach to improve radiooncological treatment
strategies with a high relative biological effectiveness
(RBE) and a high linear energy transfer (LET) compared
to conventional photon-based irradiation. Clinical benefit
of carbon ion radiotherapy (CIR) has already been demon-
strated for other tumor entities [7, 8]. For esophageal
cancer, there are some in vitro studies with CIR [9–11]
as well as one clinical phase I/II trial from Japan show-
ing first encouraging results [12]. Studies with proton
radiotherapy for lung tumors revealed a big impact of
organ and tumor motion on intrafractional dose distri-
bution in particle irradiation potentially resulting in a
severe underdosage of the target volume [13, 14].
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The purpose of this study is to generate a better un-
derstanding of the effects of organ and target motion in
carbon ion radiotherapy for esophageal cancer and to
identify appropriate treatment planning settings for dif-
ferent target localizations within the esophagus provid-
ing adequate dose robustness, target volume coverage
and sparing of the organs at risk (OAR). Our study uses
CIR as a boost treatment of the primary tumor on the
basis of beneficial bimodal treatment in other entities [8]
and preparative to a clinical trial combining a carbon
ion boost and elective IMRT of the lymphatic pathways.
Methods
Preceding data collection, the study was approved by the
institutional ethical review committee.
Patients and atasets
We retrospectively selected four 4D-CT datasets from
patients that have been treated with stereotactic body
radiotherapy (SBRT) for lung malignancies at our insti-
tution (patient 1: 81 year old female, lung cancer in
upper right lobe with 19 mm maximum diameter; pa-
tient 2: 90 year old male, lung metastasis from renal cell
carcinoma in lower left lobe with 65 mm maximum
diameter; patient 3: 81 year old female, lung metastasis
from rectal cancer in upper right lobe with 39 mm max-
imum diameter; patient 4: 71 year old male, lung cancer
in lower right lobe with 17 mm maximum diameter).
Each of these CT datasets consisted of one free-
breathing planning CT and seven co-registered 4D-CTs
in different phases of the breathing cycle (three inspira-
tory: In25%, In50%, In75%; four exspiratory: Ex0%,
Ex40%, Ex70%, Ex100%). CT scans were performed with
patients in supine position with elevated arms and with-
out abdominal compression. Slice thickness was 3 or
5 mm for the planning CT and 3 mm for the 4D-CT
scans. Comparability of Hounsfield Units (HU) between
planning CT and 4D-phases was guaranteed by calculat-
ing histograms of HU values to ensure a minimal sys-
tematic range deviation error.
Target volumes and constraints
For each patient a certain section of the esophagus was
defined as fictive gross tumor volume (GTV) on the free-
breathing planning CT representing esophageal cancer.
Consecutively, we added a caudal and cranial margin of
20 mm and a circumferential margin of 10–15 mm to ob-
tain a boost planning target volume (PTV). To simulate
variable planning scenarios with altering topographic con-
ditions, target volumes were defined in different sizes and
locations (patient 1: upper esophagus/cranio-caudal GTV
extent: 20 mm/PTV volume: 47.8 ml; patient 2: middle
esophagus/cranio-caudal GTV extent: 50 mm/PTV vol-
ume: 92.3 ml; patient 3: lower esophagus/cranio-caudal
GTV extent: 50 mm, PTV volume: 91.7 ml; patient 4:
lower esophagus/cranio-caudal GTV extent: 70 mm/PTV
volume: 223.3 ml). Organs at risk (OAR) such as lung,
heart, stomach or spinal cord were contoured on the free-
breathing planning CT. All mentioned structures were
consecutively transferred to the different 4D-CTs by elas-
tic registration with minor manual corrections afterwards.
Contouring and transformation of structures was per-
formed with a dedicated software (OnQ rts v2.0, Oncology
Systems Limited, Shrewsbury, UK).
Treatment planning
Treatment plans with 13 different field geometries
(geometry 1–13; 4× one field, 9× two fields; couch fixed,
gantry angles varied) were generated (Fig. 1) for each pa-
tient on the planning CT. Optimization of the fluences
were performed with TriP-98 (GSI Helmoltzzentrum
fuer Schwerionenforschung, Darmstadt, Germany) using
the all-points dose calculation algorithm and low-dose
LEM (local effect model) approximation. In two-field
geometries, both fields were weighted equally. Secondly,
forward dose calculation was performed separately for
each 4D-CT (‘quasi-static’). Hence, no motion interplay
was introduced. Planning CT and 4D-CT were acquired
in the same imaging session, therefore the patient was in
the same coordinate system. Correct position of the
bony anatomy was reviewed. Forward calculation of the
treatment plan was performed with TRiP-98 using the
unmodified plan created in the optimization and using
the same target point as before. Because of the large tar-
get volume of patient 4 we subsampled the dose calcula-
tion grid in the optimization step and then returned to
full dose calculation in the forward calculation. Smearing
margins technique was not used.
Plan evaluation
Indices for PTV dosage were the volume that receives at
least 95% of the prescribed dose (PTV V95%), the volume
that receives more than 107% of the prescribed dose
(PTV V107%), the median dose (PTV Dmedian), the max-
imum dose (PTV Dmax), conformity index (CI) and
homogenity index (HI). CI [15] and HI [16, 17] were de-
fined as follows:
CI ¼
Z
dVD x; y; zð ÞZ
dVD x; y; zð Þ
; 0 < CI < 1; (Integrated dose in
PTV divided by integrated dose in whole body).
HI ¼ D5−D95DPrescribed ; (D5% - D95% in PTV divided by pre-
scribed dose DP , modified based on Wu et al. [16]).
Further plan quality criteria were defined by compliance
with constraints for relevant OAR: the lung volume re-
ceiving 20% of the prescribed dose or less (V20%) < 20%,
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Fig. 1 Overview of all 13 beam geometries with specifications of the according gantry angles (GA)
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spinal cord Dmax < 60%, mean heart dose < 30% for PTVs
with major height overlap with the heart volume (i.e.
tumors located in the distal esophagus) and < 10% for
PTVs with minor or no height overlap (i.e. proximal
tumors).
To carve out the optimal beam geometry for each pa-
tient the first step included the selection of six geom-
etries with the best characteristics considering coverage/
conformity and homogeneity. In a second step, these six
geometries were evaluated by performance of sparing
the OARs. In case of multiple geometries meeting all
constraints importance ranking of the OARs was:
lungs > heart > spinal cord. The optimal beam configur-
ation for each patient was defined as the geometry in the
top spot after this two-step evaluation process.
Results
Static planning CT
PTV V95% was > 98% for all two-field geometries and >
94% for all one-field geometries. PTV V107% was < 0.3%
for all two-field geometries and < 1.2% for all one-field
geometries. PTV Dmedian was 99.6 ± 0.5% of the pre-
scribed dose independent from geometry. PTV Dmax was
< 120% of the prescribed dose except for Geometry 2
(122%) and Geometry 11 (133 %) in patient 4. CI was
> 0.82 for all one-field geometries and >0.90 for all
two-field geometries. HI was < 9.5% for all one-field
geometries and < 6% for all two-beam geometries. In
terms of OAR sparing, the lung V20% was < 22% in all
settings. Further, Dmax of the spinal cord was < 78% of
the prescribed dose for all plans. Mean heart dose was
< 1% for patient 3 and < 37% for all other patients.
4D-CTs
PTV V95% was reduced compared to the planning CT
and ranged between 50 and 95 % in patients 2, 3 and 4
and 80–98% in patient 1. In particular, geometries 5, 8,
12 and 13 performed poorly. PTV V107% was below 7%
in most cases, except for geometry 5, which showed hot
spots in up to 18% of the target volume. PTV Median
Fig. 2 Boxplots for PTV-related a) V95% b) V107% c) conformity index (CI) and d) homogeneity index (HI) for every patient as a function of beam
geometry including dosimetric information from treatment plans of all seven 4D-CT phases
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dose was 98.3 ± 3.3% and mean dose was 96.7 ± 6.7%.
PTV Dmax ranged between 110 and 123.3 % for most
cases but could reach up to 136.7% (patient 4, geo11).
Conformity Index was reduced, patient 1: CI 65–85%,
patients 2 and 3: CI 35–80%, patient 4: CI 50–85%. In
geometries 1, 2, 9, 10 and 11, the CI is > 65% for all
patients. Homogeneity Index is also depending on the
patient, patient 1: 5–25%, patient 2: 25–50%, patient 3:
15–80%, patient 4: 5–25% (except for geometry 3 with
up to 70%). Including all 4D-CT phases Fig. 2 shows
boxplots for the mentioned PTV parameters according
to beam geometry for all patients.
Boxplots for the relevant OAR constraints depending
on beam geometry and breathing phase are shown in
Fig. 3. For all geometries and 4D-CT phases the relevant
OAR dose parameters did not diverge significantly from
those calculated for the static planning CT except for
Dmax of the spinal cord in some scenarios. Figure 4 ex-
emplifies a significant dose overshoot due to a minor
heart deformation in the 4D-CT (patient 3, geo8, phase
Ex0%) compared to the initial planning CT dose distri-
bution resulting in a critical increase of Dmax in the
spinal cord from expected 16.7 % of the prescribed dose
to up to 60%.
Optimal beam configurations
Geometries 1, 2, 7, 9, 10 and 11 were universally found
to result in reliable treatment plans for all patients,
based on PTV V95% and Conformity Index, the largest
difference being the dose to the organs at risk. Taking
this into account, geometry 1 yields the optimal one-
field treatment plan for each patient, with low doses to
lungs and spinal cord and tolerable mean doses to the
heart. Using two fields, the optimal plan configurations
were more dependent on the individual patient and PTV
location: geometry 10 for patient 2, geometry 9 for pa-
tient 3 and geometry 7 for patient 4 (Fig. 5). In patient 1,
geometry 5 would be the optimal two-field treatment
plan, but it is outperformed by the single-field treatment
Fig. 3 Boxplots for a) V20% of the left lung b) V20% of the right lung c) Dmax of the spinal cord and d) mean heart dose for every patient as a
function of beam geometry including dosimetric information from treatment plans of all seven 4D-CT phases
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plan (geometry 1) due to a large PTV Dmax and PTV
V107%.
Discussion
The free-breathing planning CT is rather a merge of dif-
ferent anatomical situations over the breathing cycle
than specifically corresponding to one of the quasi-static
4D phases. Consequently, the general reduction of plan
quality in all forward calculated 4D-plans regardless of
the beam geometry was expected. However, the dimen-
sion of quality loss strongly varied depending on target
volume localization and beam configuration and mainly
affected PTV-related parameters such as coverage or ad-
equate dosage. In comparison, the impact on sparing of
the organs at risk was slightly lower, especially for mean
doses of parallel OAR, though high maximum doses to
the spinal cord could be a crucial problem.
We presented one favored beam geometry for each pa-
tient or tumor site, respectively. However, there were
further, suitable beam sets with only minimal limitations
compared to the optimal plan configuration. Accord-
ingly, there is a selection of beam configurations for
each tumor localization along the esophagus and specific
anatomy and tumor characteristics may contribute to
determining the optimal plan setting for each individual
patient. Basically, strictly anterior or posterior beam di-
rections are favorable for tumors localized in the upper
two thirds of the esophagus whereas a combination of
dorsal beam angles may be advantageous for targets in
the distal esophagus when it comes to optimizing the
mean heart dose.
Intrafractional motion-induced variations potentially
result in geometric misses because of target structures
leaving the high dose area. This problem concerns both
photon-based and particle radiotherapy. From several
studies based on 4D-CT measurements or fiducial-based
approaches we know that especially the distal esophagus
is mobile in the cranio-caudal direction up to 16 mm
dependent on breathing motion [18–21]. In an analysis
of gross tumor volume (GTV) and internal tumor vol-
ume (ITV) of carcinomas of the gastro-esophageal junc-
tion, Zhao et al. showed that ITVs were 72% larger on
average and up to 172% larger at maximum than the
corresponding GTVs and proposed asymmetrical mar-
gins up to 16 mm inferior towards the stomach [22].
Further, motion-induced variations are a particular dif-
ficulty for particle radiotherapy due to altering density
profiles alongside the radiation beam track resulting in
range deviations and displaced spread-out Bragg peaks
(SOBP). Especially the thoracic topography with moving
and close-by located tissues of low (lung) and rather
high density (e.g. heart or diaphragm) puts up a chal-
lenge for creating robust radiation treatment plans.
Severe range deviations may lead to critical dose peaks
in OAR as demonstrated for patient 2 (Fig. 4). Similar
effects have been shown by Zhang et al. for proton ir-
radiation due to different stomach gas fillings with Dmax
increases of more than 10% to the spinal cord [23].
Several different approaches in particle radiation plan-
ning have been introduced to control the mentioned
problems. The gating technique has predominantly been
established for photon-based irradiation and might be a
promising approach in CIR of moving tumors combined
with rescanning [24, 25]. Other compensation strategies
include dose smearing as analyzed for proton irradiation
of lung tumors [14, 26] or increasing the beam spot size
which has demonstrated a potential compensatory bene-
fit in CIR of liver tumors [27]. Some study groups have
also investigated dose calculations on different planning
CT phases for proton radiotherapy of lung tumors and
presented suitable solutions [13, 14, 26]. However, there
is lack of data concerning CIR planning for esophageal
tumors in particular. We were able to show that the
cornerstone for a robust treatment plan for these
Fig. 4 Dose distribution for patient 3 with geo8 calculated a) on the
free-breathing planning CT and b) on the 4D-CT phase Ex0% with a
critical overshoot due to slight variations of the left heart
contour (arrow)
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patients is accurate target volume definition and appro-
priate beam configuration respecting the individual anat-
omy, both based on 4D-CT information.
Of course, in the evaluation of treatment quality
interfractional variations have to be considered as well.
Internal changes in the patient such as location vari-
ability of the target structures, tumor response with
consecutive volume reduction or non-tumor-related
variations (e.g. pleural effusion) may lead to critical
range deviations. Additionally, daily image guidance is
recommended for photon-based radiotherapy [28] and
mandatory for particle irradiation.
Pulmonary toxicity is one of the major problems in
esophageal irradiation and increases perioperative mor-
bidity in the neoadjuvant setting dependening on the
radiation dose applied to the lungs [29] In particular,
the volume that receives doses of 5 Gy or less is an im-
portant risk factor for the development of pulmonary
complications [30]. Compared to intensity-modulated
radiotherapy (IMRT), particle radiotherapy has the po-
tential benefit to significantly reduce the lung volume
receiving lower doses. For a PTV dose of 50.4 Gy and a
GTV dose escalation up to 65.8 Gy, Welsh et al.
showed a reduction of the mean lung dose from
8.27 Gy to 3.18 Gy in favor of proton treatment [31].
The analysis of the dose volume histograms (DVH)
revealed that dose reduction was mainly attained by
minimizing low dose areas. However, an optimal spar-
ing of the lungs is often accomplished at the expense of
a higher heart dose [23]. Several studies observed that
radiotherapy potentially impairs functional cardiac pa-
rameters such as myocardial perfusion of the inferior
left ventricle [32] or cardiac volume with hemodynamic
impact [33]. Cardiac toxicity is probably underesti-
mated in esophageal irradiation [34], but the level of
clinical relevance of cardiac long-terms effects is un-
clear due to the limited prognosis of esophageal cancer.
For both, pulmonary and cardiac toxicity, CIR has the
potential to reduce mean organ doses hence improving
the incidence and degree of side effects.
We presented suitable beam configurations for a car-
bon ion boost to the primary site in the esophagus. Valid
and robust CIR for larger volumes like the regional
lymphatic pathways treated with elective nodal irradi-
ation (ENI) according to the current recommendations
is considerably harder to achieve. However, in case of a
further validation and more evidence for the safety of
involved-field radiotherapy (IF-RT) in esophageal cancer
patients resulting in smaller treatment volumes [35, 36],
CIR has the potential to suitably cover tumor boost as
well as lymphatic target volumes.
Clinical experience with particle radiotherapy for
esophageal cancer is small. At MD Anderson Cancer
Center Lin et al. treated 62 patients with proton radio-
therapy combined with simultaneous chemotherapy in a
definitive or neoadjuvant setting up to a median dose of
50.4 Gy and presented very low toxicity rates [37]. A
phase I/II trial from Japan offers the only clinical experi-
ence of CIR in esophageal cancer patients available today
[12]. In a neoadjuvant setting 31 patients were treated
with cumulative doses between 28.8 Gy (RBE) and
36.8 Gy (RBE) in 8 fractions. An encouraging rate of
pathological complete remission of 38.7% could be
achieved with very low toxicity at the same time.
Fig. 5 Optimal beam configuration for a) patient 1 (geo1), b) patient 2 (geo10), c) patient 3 (geo9) and d) patient 4 (geo7)
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However, PTV margins were defined rather small (GTV
+ 30 mm for cranial and caudal borders) and dose
schemes do not meet current recommendations. Further
research is necessary to define effective and safe dosage
regimens for CIR. Special attention has to be paid to the
esophagus itself as an organ at risk as well as the stom-
ach for distal tumors being prone to complications with
increased radiation dose [38].
Conclusion
Carbon ion radiotherapy for esophageal cancer is feas-
ible with robust dose calculations when variable, intra-
fractional factors are considered that potentially impair
plan quality. Depending on localization and size of the
tumor there are several beam configurations that allow
an adequate dose coverage and sparing of the organs at
risk at the same time. In the future, prospective and
randomized trials are necessary to determine the clin-
ical impact of carbon ion radiotherapy on outcome and
toxicity.
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